Elacestrant plus alpelisib in an and co-mutated and heavily pretreated metastatic breast cancer: the first case report for combination efficacy and safety

Elacestrant plus alpelisib in an and co-mutated and heavily pretreated metastatic breast cancer: the first case report for combination efficacy and safety

Breast cancer (BC) is the leading cause of cancer-related mortality among women, and hormone receptor (HR)-positive subtype makes up the majority of all cases. The standard of care in HR + /HER2 − metastatic BC (MBC) is endocrine therapy (ET) plus a CDK4/6 inhibitor (CDK4/6i). ESR1 mutations could i...

Full description

Saved in:
Bibliographic Details
Main Authors: Ünal Metin Tokat, Şevval Nur Bilgiç, Esranur Aydın, Ashkan Adibi, Eylül Özgü, Onur Tutar, Mutlu Demiray
Format: Article
Language:English
Published: SAGE Publishing 2024-11-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359241297101
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items